Company intelligence / Profile preview

Wugen

St. Louis, Missouri, USAwugen.com ↗
Ownership
Private
Employees
~200
Development stage
Other
01

Overview

Wugen’s lead program, WU-CART‑007, is an off-the-shelf allogeneic CD7-targeted CAR-T therapy that has shown clinically manageable safety and anti-leukemic activity in relapsed/refractory T‑ALL/LBL patients. Phase 2 data demonstrated high efficacy surpassing standard of care. The company has initiated a pivotal trial following positive results and received RMAT and PRIME designations to accelerate regulatory review. Additional programs include memory NK cell therapies in early clinical or preclinical development targeting AML and solid tumors.

Therapeutic areas
Oncology
Modalities
Allogeneic CAR-T cell therapiesMemory natural killer (NK) cell therapiesEngineered NK cellsMonoclonal antibody combinations (for solid tumors)
Industry
Biotech
02

Drug pipeline

15 assets

CD7-CART01

2

14 more assets in the full pipeline.

03

Partnerships

Co-development partnerships in China, Hong Kong, Taiwan, Macao, Singapore for product development/commercialization

Beyond the preview

Go deeper on Wugen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wugen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call